Text Size

Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Hospital Authority, Hong Kong.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
The University of Hong Kong
Fresienius Kabi HK Ltd
Information provided by:
Hospital Authority, Hong Kong
ClinicalTrials.gov Identifier:
NCT00563498
First received: November 21, 2007
Last updated: July 6, 2010
Last verified: July 2010
History of Changes
  Purpose

The primary purpose of this project is to investigate if addition of glutamine, an amino acid, to standard parenteral nutrition, may improve the clinical outcome of the bone marrrow transplantation reducing the occurrence of veno-occlusive disease and severity of mucositis.


Condition Intervention
Pulmonary Veno-Occlusive Disease
Hepatic Veno-Occlusive Disease
Mucositis
 Drug: Glutamine

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: A Randomized Control Studies on the Effects of Glutamine on the Clinical Outcome of Bone Marrow Transplant Recipients With Special Reference to Veno-occlusive Disease and Mucositis.

Resource links provided by NLM:

Drug Information available for: Glutamine
U.S. FDA Resources

Further study details as provided by Hospital Authority, Hong Kong:

Primary Outcome Measures:
  • Veno-occlusive disease [ Time Frame: 1 month ]
  • Mucositis [ Time Frame: 1 month ]

Secondary Outcome Measures:
  • Hospital stay [ Time Frame: 2 months ]
  • Use of antibiotics [ Time Frame: 2 months ]

Estimated Enrollment: 40
Study Start Date: July 2004
Estimated Study Completion Date: June 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Allogeneic bone marrow transplant recipients using busulfan and cyclophosphamide as conditioning.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00563498

Contacts
Contact: YH Leung, Dr (852) 2855 3347 ayhleung@hku.hk

Locations
China
Queen Mary Hospital Recruiting
Hong Kong, China
Sub-Investigator: YH Leung, Dr            
Sub-Investigator: Raymond Liang, Prof            
Sponsors and Collaborators
Hospital Authority, Hong Kong
The University of Hong Kong
Fresienius Kabi HK Ltd
Investigators
Principal Investigator: Albert Lie, Dr Department of Medicine/Division of Haematology, Queen Mary Hospital/ The University of Hong Kong
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00563498     History of Changes
Other Study ID Numbers: EC1432-00, HARECCTR0500034
Study First Received: November 21, 2007
Last Updated: July 6, 2010
Health Authority: Hong Kong: Ethics Committee

Keywords provided by Hospital Authority, Hong Kong:
Veno-occlusive disease
Mucositis

Additional relevant MeSH terms:
Hepatic Veno-Occlusive Disease
Budd-Chiari Syndrome
Pulmonary Veno-Occlusive Disease
Mucositis
Liver Diseases
Digestive System Diseases
Vascular Diseases
Cardiovascular Diseases
Venous Thrombosis
 Thrombosis
Embolism and Thrombosis
Lung Diseases
Respiratory Tract Diseases
Gastroenteritis
Gastrointestinal Diseases
Mouth Diseases
Stomatognathic Diseases

ClinicalTrials.gov processed this record on October 17, 2012